Faculty, Staff and Student Publications
Publication Date
1-1-2023
Journal
Cancer Investigation
DOI
10.1080/07357907.2022.2136681
PMID
36239611
PMCID
PMC12309038
PubMedCentral® Posted Date
7-30-2025
PubMedCentral® Full Text Version
Author MSS
Abstract
The COSMIC-313 phase 3 randomized controlled trial tested the triplet combination of cabozantinib with nivolumab and ipilimumab in comparison with nivolumab plus ipilimumab control as fist-line systemic therapy in metastatic clear cell renal cell carcinoma. The first results presented at the 2022 European Society of Medical Oncology Congress are a milestone for the renal cell carcinoma field because they signal the advent of triplet combinations as potential treatment options for our patients. The present commentary highlights some considerations and potential next steps based on these first impressions.
Keywords
Humans, Nivolumab, Ipilimumab, Kidney Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Renal cell carcinoma, cabozantinib, clinical trials, ipilimumab, nivolumab
Published Open-Access
yes
Recommended Citation
Pavlos Msaouel, "Less is More? First Impressions From COSMIC-313" (2023). Faculty, Staff and Student Publications. 4848.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4848
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons